A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit

References

1. ↵
   1. Denning DW

   (1998) Invasive aspergillosis. Clin Infect Dis 26:781–803, quiz 804-805.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. Taccone FS,
   2. Van den Abeele AM,
   3. Bulpa P,
   4. Misset B,
   5. Meersseman W,
   6. Cardoso T,
   7. et al.

   (2015) Epidemiology of invasive aspergillosis in critically ill patients:clinical presentation, underlying conditions, and outcomes. Crit Care 19:7.

   OpenUrlCrossRefPubMed
3. ↵
   1. Dagenais TR,
   2. Keller NP

   (2009) Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev 22:447–465.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. Kosmidis C,
   2. Denning DW

   (2015) The clinical spectrum of pulmonary aspergillosis. Thorax 70:270–277.

   OpenUrlAbstract/FREE Full Text
5. ↵
   1. Vallabhaneni S,
   2. Benedict K,
   3. Derado G,
   4. Mody RK

   (2017) Trends in hospitalizations related to invasive Aspergillosis and Mucormycosis in the United States, 2000-2013. Open Forum Infect Dis 4:ofw268.

   OpenUrl
6. ↵
   1. Chen J,
   2. Yang Q,
   3. Huang J,
   4. Li L

   (2014) Clinical findings in 19 cases of invasive pulmonary aspergillosis with liver cirrhosis. Multidiscip Respir Med 9:1–5.

   OpenUrl
7. ↵
   1. van de Veerdonk FL,
   2. Kolwijck E,
   3. Lestrade PP,
   4. Hodiamont CJ,
   5. Rijnders BJ,
   6. van Paassen J,
   7. et al.

   (2017) Influenza-Associated Aspergillosis in critically ill patients. Am J Respir Crit Care Med, [Epub ahead of print].
8. ↵
   1. Schwarz C,
   2. Brandt C,
   3. Whitaker P,
   4. Sutharsan S,
   5. Skopnik H,
   6. Gartner S,
   7. et al.

   (2018) Invasive pulmonary fungal infections in cystic fibrosis. Mycopathologia 183:33–43.

   OpenUrl
9. ↵
   1. Rotjanapan P,
   2. Chen YC,
   3. Chakrabarti A,
   4. Li RY,
   5. Rudramurthy SM,
   6. Yu J,
   7. et al.

   (2018) Erratum:Epidemiology and clinical characteristics of invasive mould infections:A multicenter, retrospective analysis in five Asian countries. Med Mycol 56:387.

   OpenUrl
10. ↵
    1. Dimopoulos G,
    2. Frantzeskaki F,
    3. Poulakou G,
    4. Armaganidis A

    (2012) Invasive aspergillosis in the intensive care unit. Ann N Y Acad Sci 1272:31–39.

    OpenUrlCrossRefPubMedWeb of Science
11. ↵
    1. Bassetti M,
    2. Bouza E

    (2017) Invasive mould infections in the ICU setting:complexities and solutions. J Antimicrob Chemother 72:i39–i47.

    OpenUrlCrossRef
12. ↵
    1. Bassetti M,
    2. Garnacho-Montero J,
    3. Calandra T,
    4. Kullberg B,
    5. Dimopoulos G,
    6. Azoulay E,
    7. et al.

    (2017) Intensive care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med 43:1225–1238.

    OpenUrlPubMed
13. ↵
    1. Leeflang MM,
    2. Debets-Ossenkopp YJ,
    3. Wang J,
    4. Visser CE,
    5. Scholten RJ,
    6. Hooft L,
    7. et al.

    (2015) Galactomannan detection for invasive aspergillosis in immunocompromised patients. Cochrane Database Syst Rev, CD007394.
14. ↵
    1. Zhou W,
    2. Li H,
    3. Zhang Y,
    4. Huang M,
    5. He Q,
    6. Li P,
    7. et al.

    (2017) Diagnostic value of galactomannan antigen test in serum and bronchoalveolar lavage fluid samples from patients with nonneutropenic invasive pulmonary aspergillosis. J Clin Microbiol 55:2153–2161.

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Schroeder M,
    2. Simon M,
    3. Katchanov J,
    4. Wijaya C,
    5. Rohde H,
    6. Christner M,
    7. et al.

    (2016) Does galactomannan testing increase diagnostic accuracy for IPA in the ICU?A prospective observational study. Crit Care 20:139.

    OpenUrlCrossRef
16. ↵
    1. De Pauw B,
    2. Walsh TJ,
    3. Donnelly JP,
    4. Stevens DA,
    5. Edwards JE,
    6. Calandra T,
    7. et al.

    (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821.

    OpenUrlCrossRefPubMedWeb of Science
17. ↵
    1. Blot SI,
    2. Taccone FS,
    3. Van den Abeele AM,
    4. Bulpa P,
    5. Meersseman W,
    6. Brusselaers N,
    7. et al.

    (2012) A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 186:56–64.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    1. Huang L,
    2. He H,
    3. Jin J,
    4. Zhan Q

    (2017) Is Bulpa criteria suitable for the diagnosis of probable invasive pulmonary Aspergillosis in critically ill patients with chronic obstructive pulmonary disease?A comparative study with EORTC/ MSG and ICU criteria. BMC Infect Dis 17:209.

    OpenUrlCrossRef
19. ↵
    1. Hope WW,
    2. Petraitis V,
    3. Petraitiene R,
    4. Aghamolla T,
    5. Bacher J,
    6. Walsh TJ

    (2010) The initial 96 hours of invasive pulmonary aspergillosis:histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 54:4879–4886.

    OpenUrlAbstract/FREE Full Text
20. ↵
    1. Chakrabarti A,
    2. Chatterjee SS,
    3. Das A,
    4. Shivaprakash MR

    (2011) Invasive aspergillosis in developing countries. Med Mycol 49:S35–S47.

    OpenUrlCrossRefPubMed
21. ↵
    1. Baddley JW,
    2. Stephens JM,
    3. Ji X,
    4. Gao X,
    5. Schlamm HT,
    6. Tarallo M

    (2013) Aspergillosis in Intensive Care Unit (ICU) patients:epidemiology and economic outcomes. BMC Infect Dis 13:29.

    OpenUrlCrossRefPubMed
22. ↵
    1. Tortorano AM,
    2. Esposto MC,
    3. Prigitano A,
    4. Grancini A,
    5. Ossi C,
    6. Cavanna C,
    7. et al.

    (2012) Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol 50:1051–1053.

    OpenUrlAbstract/FREE Full Text
23. ↵
    1. Verweij PE,
    2. Chowdhary A,
    3. Melchers WJ,
    4. Meis JF

    (2016) Azole Resistance in Aspergillus fumigatus:Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? Clin Infect Dis 62:362–368.

    OpenUrlCrossRefPubMed
24. ↵
    1. Okuturlar Y,
    2. Ozkalemkas F,
    3. Ener B,
    4. Serin SO,
    5. Kazak E,
    6. Ozcelik T,
    7. et al.

    (2015) Serum galactomannan levels in the diagnosis of invasive aspergillosis. Korean J Intern Med 30:899–905.

    OpenUrl
25. ↵
    1. Racil Z,
    2. Kocmanova I,
    3. Toskova M,
    4. Buresova L,
    5. Weinbergerova B,
    6. Lengerova M,
    7. et al.

    (2011) Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 15:e874–e881.

    OpenUrlCrossRefPubMed
26. ↵
    1. Hope WW,
    2. Kruhlak MJ,
    3. Lyman CA,
    4. Petraitiene R,
    5. Petraitis V,
    6. Francesconi A,
    7. et al.

    (2007) Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis:implications for antifungal therapy. J Infect Dis 195:455–466.

    OpenUrlCrossRefPubMedWeb of Science
27. ↵
    1. Cordonnier C,
    2. Botterel F,
    3. Ben Amor R,
    4. Pautas C,
    5. Maury S,
    6. Kuentz M,
    7. et al.

    (2009) Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect 15:81–86.

    OpenUrlPubMedWeb of Science
28. ↵
    1. Maertens J,
    2. Verhaegen J,
    3. Lagrou K,
    4. Van Eldere J,
    5. Boogaerts M

    (2001) Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients:a prospective validation. Blood 97:1604–1610.

    OpenUrlAbstract/FREE Full Text
29. ↵
    1. Heng SC,
    2. Chen SC,
    3. Morrissey CO,
    4. Thursky K,
    5. Manser RL,
    6. De Silva HD,
    7. et al.

    (2014) Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagn Microbiol Infect Dis 79:322–327.

    OpenUrlCrossRefPubMed
30. ↵
    1. Denning DW,
    2. Page ID,
    3. Chakaya J,
    4. Jabeen K,
    5. Jude CM,
    6. Cornet M,
    7. et al.

    (2018) Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings. Emerg Infect Dis, 24.
31. ↵
    1. Morton CO,
    2. White PL,
    3. Barnes RA,
    4. Klingspor L,
    5. Cuenca-Estrella M,
    6. Lagrou K,
    7. et al.

    (2017) Determining the analytical specificity of PCR-based assays for the diagnosis of IA:What is Aspergillus? Med Mycol 55:402–413.

    OpenUrl
32. ↵
    1. Ullmann AJ,
    2. Aguado JM,
    3. Arikan-Akdagli S,
    4. Denning DW,
    5. Groll AH,
    6. Lagrou K,
    7. et al.

    (2018) Diagnosis and management of Aspergillus diseases:executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect 24:e1–e38.

    OpenUrl